FDA Grants Priority Review to Expand Indication of GSK's Arexvy for RSV Protection in Adults Aged 50-59 Years

The FDA assigned a Prescription Drug User Fee Act action date of June 7, 2024, to an application that would expand the indication of Arexvy to include adults 50-59 years with an increased risk of respiratory syncytial virus-related lower respiratory tract disease.